AbbVie To Continue Study Of ABT-414 For Glioblastoma Multiforme Brain Cancer

(RTTNews) - Research-based biopharmaceutical company AbbVie Inc. (ABBV) Friday reported preliminary results from an ongoing Phase I trial of its investigational compound ABT-414, in patients with recurrent glioblastoma multiforme, most common and most aggressive type of malignant primary brain tumor. The results showed four objective responses, including one complete response among the treated patients.

The Phase I, open-label, multicenter, international trial was designed to evaluate the safety and efficacy of ABT-414 when administered every other week in combination with temozolomide in patients with recurrent glioblastoma. Other important assessments included adverse events, pharmacokinetic parameters, objective response and tumor tissue epidermal growth factor receptor biomarkers.

As a result of the complete response and three partial responses, the company plans to continue further evaluation of ABT-414 in patients with glioblastoma multiforme.